menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
Filtered by 'NHS' ×
John Procter
A joint working approach allows biopharma to pool resources and collaborate with the NHS to improve patient care.
Read More
Gavin Jones
While the chance of survival for people with cancer is increasing overall, the disease remains the most common cause of death in the UK, leading to 29% of all deaths in 2013 1 , and the numbers of diagnoses continue to rise year on year. Cancer is a key priority for the UK public and for the government. This is putting a financial burden on the NHS, whose healthcare budgets are already being squeezed by a combination of the aging population and the UK government's austerity measures. Given increased rates of early diagnosis alongside improved duration of patient outcomes cancer is now often being viewed as a long term condition rather than an acute event with poor prognoses. This is also putting pressure on service provision that can only grow given further innovations in treatment and...
Read More
Peter Rutherford
MSLs can provide a bridge between biopharma and healthcare professionals, allowing them to engage and share scientific information to physicians and payers.
Read More
DeanSummerfield
Cancer science has evolved fast over the past decade. Better knowledge of basic cancer biology based on increased understanding of cell signalling and mechanism of disease, and greater access to genomics and other 'omics' data has led to the rapid development of precision medicine and the growth of immuno-therapeutics. The challenge of innovation: Spoiled for choice? New drugs with their new targets and new mechanisms of action, and their greater specificity, safety and efficacy, combined with earlier and more accurate diagnoses, have led to improvements in patient’s outcomes and survival. This has benefits not only for the patients and their families, but to society as a whole. These innovative therapies add extra layers of complexity to diagnosing and treating cancer. For...
Read More
Ingrid Martin
Six Sigma, originally developed at Motorola in the mid-1980s , aims to improve quality and efficiency of processes by reducing variability and error. Adding in the principles of lean manufacturing has created Lean Six Sigma, which has a focus on eliminating waste as a way to improve outcomes. So – what does Lean Six Sigma have to do with health? While it was developed as a manufacturing tool, Lean Six Sigma can be applied to many areas that deliver services through standardized processes. This includes the NHS, which can be likened to a production line, where patients enter the system at one 'end', receive treatment (whether acute or chronic) and are then discharged at the other. Lean Six Sigma: Capabilities in change management At Quintiles, we define Lean Six Sigma as change...
Read More
PaulSutton
Oncology is a growing area, with new breakthroughs being made and innovative cancer therapeutics reaching the market. However, there are still barriers to market access, which could be overcome by the use of local data. The patients In 2009, there were around two million cancer survivors in the UK. As the UK population grows and ages, and as the survival rate for cancer improves, these numbers are expected to grow at around a million per decade, rising to around 5.3 million in 2040 1 . Source: Maddams et al . 1 This growth rate is expected to be higher in older patients and in the longest survivors, but overall is likely to slow down 1 . Amongst cancer survivors, around one in four are living with the after effects of cancer treatment, including poor health and...
Read More
Peter Rutherford
In June 2015, Quintiles Integrated Market Access team members, along with voluntary and patient organization leads, representatives from charities, NGOs and the pharma industry, senior clinical and commercial NHS leaders, healthcare professional body representatives and politicians from all parties, were invited to take part in an informal 2020health post-election reception. This was hosted by Bernard Jenkin MP at the House of Commons and addressed by Simon Stevens, Chief Executive of NHS England. Stevens took this opportunity, the first in front of this type of audience following the election, to offer an insight into NHS England strategy and delivery and talk about three Ps – the pride of staff working in NHS England, the pressures facing healthcare, and the possibilities that exist to...
Read More
Demonstrating value through cross-functional teams
The pressure for biopharma companies to provide specific and nuanced data to demonstrate the value of their therapies has never been greater. Scientific data supporting safety and efficacy is no longer enough for a product to achieve approval and commercial success. In today’s healthcare economy, every stakeholder group in the value chain expects to see data that meets their unique needs, and when companies fail to provide this data, otherwise promising products can fall flat. To avoid such risk, companies need to change the kinds of data they collect for their regulatory, clinical, market access, medical and commercial strategies, and how that data is used in the development process. Given that different stakeholders measure value in different ways, with each demanding a different set...
Read More
PaulSutton
Both outcomes audits and outcomes evaluations are powerful research tools designed to collect and interpret real-world data for a specific patient population. Whereas an outcomes audit uses data extraction retrospectively to view a patient’s progression on a drug treatment, an outcomes evaluation is more of a prospective process – comparing initial measurements from a patient with measurements taken at intervals during the course of their treatment. Previously, we have written how an outcomes evaluation can benefit biopharma, however in this article we will examine how outcomes evaluations can help the NHS to optimally manage its patients by tracking clinical and economic drug outcomes. Real-world data challenges facing the NHS The NHS is under pressure to deliver efficient...
Read More
Gavin Jones
In this post, I will examine outcomes evaluations and how they can help biopharma demonstrate value and outcomes at a local level in the UK. For biopharma, proving the value of a drug is key to its success in the local health economy. During the process of determining a drug’s effectiveness within a local heath economy it is important that all potential data sources are utilised when developing a case for funding with decision makers and a local outcomes assessment can be an important element of this case presentation. With this in mind, outcomes evaluations and outcomes audits are suitable methods for proving a drug’s value and measuring treatment effectiveness using observational data.  We have previously discussed outcomes audits in detail, however this approach looks at data...
Read More